EP0831920A4 - Neues cathepsin sowie verfahren und zusammensetzungen zur inhibierung desselben - Google Patents

Neues cathepsin sowie verfahren und zusammensetzungen zur inhibierung desselben

Info

Publication number
EP0831920A4
EP0831920A4 EP96913917A EP96913917A EP0831920A4 EP 0831920 A4 EP0831920 A4 EP 0831920A4 EP 96913917 A EP96913917 A EP 96913917A EP 96913917 A EP96913917 A EP 96913917A EP 0831920 A4 EP0831920 A4 EP 0831920A4
Authority
EP
European Patent Office
Prior art keywords
inhibition
compositions
methods
novel cathepsin
cathepsin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96913917A
Other languages
English (en)
French (fr)
Other versions
EP0831920A1 (de
Inventor
Jay S Tung
Sukanto Sinha
Lisa Mcconlogue
Gwen Tatsuno
John Anderson
Christopher M F Semko
Susanna Chrysler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perrigo Co PLC
Original Assignee
Athena Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/469,362 external-priority patent/US5849711A/en
Priority claimed from US08/467,607 external-priority patent/US5783434A/en
Application filed by Athena Neurosciences Inc filed Critical Athena Neurosciences Inc
Publication of EP0831920A1 publication Critical patent/EP0831920A1/de
Publication of EP0831920A4 publication Critical patent/EP0831920A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
EP96913917A 1995-06-06 1996-04-26 Neues cathepsin sowie verfahren und zusammensetzungen zur inhibierung desselben Withdrawn EP0831920A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US469362 1983-02-24
US467607 1990-01-19
US08/469,362 US5849711A (en) 1995-06-06 1995-06-06 Cathepsin and methods and compositions for inhibition thereof
US08/467,607 US5783434A (en) 1995-06-06 1995-06-06 Cathepsin and methods and compositions for inhibition thereof
PCT/US1996/006211 WO1996039194A1 (en) 1995-06-06 1996-04-26 Novel cathepsin and methods and compositions for inhibition thereof

Publications (2)

Publication Number Publication Date
EP0831920A1 EP0831920A1 (de) 1998-04-01
EP0831920A4 true EP0831920A4 (de) 2003-03-19

Family

ID=27042111

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96913917A Withdrawn EP0831920A4 (de) 1995-06-06 1996-04-26 Neues cathepsin sowie verfahren und zusammensetzungen zur inhibierung desselben

Country Status (4)

Country Link
EP (1) EP0831920A4 (de)
JP (1) JPH11506923A (de)
CA (1) CA2221684A1 (de)
WO (1) WO1996039194A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE377006T1 (de) * 1995-11-28 2007-11-15 Cephalon Inc Aus d-aminosäuren abgeleitete cystein- und serinproteasehemmer
US5965614A (en) 1996-11-22 1999-10-12 Athena Neurosciences, Inc. N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
AR016751A1 (es) * 1996-11-22 2001-08-01 Athena Neurosciences Inc Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo
US6153652A (en) 1996-11-22 2000-11-28 Elan Pharmaceuticals, Inc. N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
JP2001504498A (ja) * 1996-11-22 2001-04-03 エラン・ファーマシューティカルズ・インコーポレイテッド Ｎ―（アリール／ヘテロアリール／アルキルアセチル）アミノ酸アミドおよびその医薬組成物、並びに該化合物を用いたβ―アミロイドペプチドの放出および／またはその合成を阻害する方法
US6117901A (en) 1996-11-22 2000-09-12 Athena Neurosciences, Inc. N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for use
US6191166B1 (en) 1997-11-21 2001-02-20 Elan Pharmaceuticals, Inc. Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6642261B2 (en) 1997-11-21 2003-11-04 Athena Neurosciences, Inc. N-(aryl/heteroarylacety) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6207710B1 (en) 1996-11-22 2001-03-27 Elan Pharmaceuticals, Inc. Compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6211235B1 (en) 1996-11-22 2001-04-03 Elan Pharmaceuticals, Inc. Compounds for inhibiting β-amyloid peptide release and/or its synthesis
DE19648793A1 (de) * 1996-11-26 1998-05-28 Basf Ag Neue Benzamide und deren Anwendung
AR011164A1 (es) * 1997-02-28 2000-08-02 Lilly Co Eli Compuestos heterociclicos, composiciones farmaceuticas que los comprenden, y metodos para inhibir la liberacion del peptido beta-amiloide y/o su sintesismediante el uso de dichos compuestos
AU1926699A (en) * 1997-12-18 1999-07-05 Immunex Corporation Cathepsin dc proteins, dna encoding the proteins, and their use in human cancer prognosis
US6506782B1 (en) 1998-02-27 2003-01-14 Athena Neurosciences, Inc. Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
WO1999054320A1 (de) * 1998-04-20 1999-10-28 Basf Aktiengesellschaft Neue heterocyclisch substituierte amide mit cystein-protease hemmender wirkung
DE19818614A1 (de) 1998-04-20 1999-10-21 Basf Ag Neue substituierte Amide, deren Herstellung und Anwendung
WO2000024392A1 (en) * 1998-10-26 2000-05-04 Sumitomo Pharmaceuticals Company, Limited β-AMYLOID FORMATION INHIBITORS
ES2296834T3 (es) * 2002-02-14 2008-05-01 Biofrontera Pharmaceuticals Ag Inhibidores de la catepsina y para el desarrollo de un medicamento para el tratamiento del dolor.
EP1497642A2 (de) 2002-03-19 2005-01-19 Tularik, Inc. Genamplifizierung bei krebs
EP1347059A1 (de) * 2002-03-20 2003-09-24 Biofrontera Pharmaceuticals AG Cathepsin y fur die entwicklung von arzneimitteln zur behandlung von cerebrales ödem
US8263044B2 (en) * 2005-11-10 2012-09-11 Orchid Research Laboratories Limited Stilbene like compounds as novel HDAC inhibitors

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009838A1 (en) * 1993-10-01 1995-04-13 Merrell Pharmaceuticals Inc. INHIBITORS OF β-AMYLOID PROTEIN PRODUCTION
EP0652009A1 (de) * 1993-08-09 1995-05-10 Eli Lilly And Company Identifizierung und Verwendung von Aspartylproteaseinhibitoren
WO1995013084A1 (en) * 1992-05-11 1995-05-18 Miles Inc. Cathepsin d is an amyloidogenic protease in alzheimer's disease
EP0659418A1 (de) * 1993-12-21 1995-06-28 Eli Lilly And Company 2-Phenyl-3-Azoylbenzothiopene zur Behandlung der Alzheimerkrankheit
EP0670309A1 (de) * 1992-11-20 1995-09-06 Japan Tobacco Inc. Verbindung mit prolye-endopeptidase inhibierender aktivität und ihre pharmazeutische verwendung
WO1996020725A2 (en) * 1995-01-06 1996-07-11 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
WO1996022966A1 (en) * 1995-01-23 1996-08-01 Biogen, Inc. Cell adhesion inhibitors
EP0732399A2 (de) * 1990-03-05 1996-09-18 Cephalon, Inc. Chymotrypsinartige Proteasen und ihre Inhibitoren
WO1997030072A1 (en) * 1996-02-20 1997-08-21 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Peptidomimetic inhibitors of cathepsin d and plasmepsins i and ii

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221607A (en) * 1989-09-18 1993-06-22 Scios Nova Inc. Assays and reagents for amyloid deposition
US5242932A (en) * 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
US5164295A (en) * 1991-03-06 1992-11-17 The Upjohn Company Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds
US5538845A (en) * 1992-02-05 1996-07-23 Athena Neurosciences, Inc. Beta-amyloid peptide production inhibitors and methods for their identification
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
NZ248573A (en) * 1992-09-10 1996-02-27 Lilly Co Eli 5-arylmethyl (and methylidene) thiazolidin-4-one derivatives; their preparation and pharmaceutical compositions
US5478857A (en) * 1993-12-23 1995-12-26 Eli Lilly And Company Use of PLA2 inhibitors as treatment for alzheimer's disease
WO1995031192A1 (en) * 1994-05-16 1995-11-23 Thomas Jefferson University Method and use of agents to inhibit protein polymerization and methods of identifying these agents
CA2152765A1 (en) * 1994-06-30 1995-12-31 Jeroen Elisabeth-Joseph Knops Methods for treating a physiological disorder associated with beta amyloid peptide
US5523295A (en) * 1994-07-06 1996-06-04 Brandeis University Method for treating and preventing alzheimer's disease

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0732399A2 (de) * 1990-03-05 1996-09-18 Cephalon, Inc. Chymotrypsinartige Proteasen und ihre Inhibitoren
WO1995013084A1 (en) * 1992-05-11 1995-05-18 Miles Inc. Cathepsin d is an amyloidogenic protease in alzheimer's disease
EP0670309A1 (de) * 1992-11-20 1995-09-06 Japan Tobacco Inc. Verbindung mit prolye-endopeptidase inhibierender aktivität und ihre pharmazeutische verwendung
EP0652009A1 (de) * 1993-08-09 1995-05-10 Eli Lilly And Company Identifizierung und Verwendung von Aspartylproteaseinhibitoren
WO1995009838A1 (en) * 1993-10-01 1995-04-13 Merrell Pharmaceuticals Inc. INHIBITORS OF β-AMYLOID PROTEIN PRODUCTION
EP0659418A1 (de) * 1993-12-21 1995-06-28 Eli Lilly And Company 2-Phenyl-3-Azoylbenzothiopene zur Behandlung der Alzheimerkrankheit
WO1996020725A2 (en) * 1995-01-06 1996-07-11 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
WO1996022966A1 (en) * 1995-01-23 1996-08-01 Biogen, Inc. Cell adhesion inhibitors
WO1997030072A1 (en) * 1996-02-20 1997-08-21 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Peptidomimetic inhibitors of cathepsin d and plasmepsins i and ii

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9639194A1 *

Also Published As

Publication number Publication date
WO1996039194A1 (en) 1996-12-12
EP0831920A1 (de) 1998-04-01
CA2221684A1 (en) 1996-12-12
JPH11506923A (ja) 1999-06-22

Similar Documents

Publication Publication Date Title
EG20993A (en) Cleasing compositions
EG20989A (en) Cleasing compositions
EP0831920A4 (de) Neues cathepsin sowie verfahren und zusammensetzungen zur inhibierung desselben
GB9613043D0 (en) Improved compositions
IL122788A0 (en) Sunscreen compositions
HUP9900925A3 (en) Sunscreen compositions
PL321759A1 (en) Novel thrombosin inhibitors
GB9614911D0 (en) Sunscreen compositions
IL121167A0 (en) Method of inhibiting cathepsin K
GB9500577D0 (en) Compositions
ZA9510052B (en) Sunscreen compositions
EP0733547A3 (de) Ablatorzusammensetzungen
GB9516909D0 (en) Refrigerant compositions
GB9508791D0 (en) Compositions of matter
GB9504996D0 (en) Compositions
GB9516920D0 (en) Refrigerant compositions
ZA961514B (en) Novel compositions
HUP9601550A2 (en) Particulale compositions
GB9515805D0 (en) Compositions
GB9510719D0 (en) Novel compositions
GB9510563D0 (en) Well inhibition
GB9508785D0 (en) Novel compositions
GB9604856D0 (en) Compositions
GB9510222D0 (en) Compositions of matter
GB9517113D0 (en) Novel compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971204

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 48/00 A, 7C 12Q 1/68 B, 7C 07H 21/02 B, 7C 07H 21/04 B, 7C 07K 5/06 B

A4 Supplementary search report drawn up and despatched

Effective date: 20030131

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20021101